市場調查報告書

全球類血友病病(VWD)治療市場 2019年∼2023年

Global Von Willebrand Disease Treatment Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 754255
出版日期 內容資訊 英文 115 Pages
商品交期: 最快1-2個工作天內
價格
全球類血友病病(VWD)治療市場 2019年∼2023年 Global Von Willebrand Disease Treatment Market 2019-2023
出版日期: 2018年11月22日內容資訊: 英文 115 Pages
簡介

類血友病病(VWD),是先天性的疾病,能觀察到鼻血、手術中及術後的大量出血等症狀。全球類血友病病(VWD)治療市場,因為患者支援計劃的增加而促進成長,另一方面,由於是稀少的血液疾病,研究費及治療費高,對患者來說成本高是課題之一。全球類血友病病(VWD)治療市場預測直至2023年將以約7%的年複合成長率發展。

本報告提供全球類血友病病(VWD)治療市場調查,市場概要,各治療方法、各地區的市場規模的變化與預測,市場成長要素及課題分析,市場成長要素及課題分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模的預測

第5章 波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入業者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係
  • 市場情形

第6章 市場區隔:各治療法

  • 市場區隔:各治療法
  • 市場比較:各治療法
  • 去氨加壓素給藥
  • 補充療法
  • 其他
  • 市場機會:各治療法

第7章 客戶形勢

第8章 地區形勢

  • 市場區隔:各地區
  • 市場比較:各地區
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區
  • 市場牽引國
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • Shire

第14章 附錄

  • 調查方法
  • 簡稱的清單

第15章 關於Technavio

目錄
Product Code: IRTNTR30291

About this market

The increasing awareness about VWD is likely to boost growth in the market. VWD will be present in the affected individual since the time of birth; however, the symptoms do not appear from childhood. Patients' perceptions of symptoms such as frequent nosebleeds, staining and extreme bleeding during and after invasive events such as dental extractions and surgical procedures are general changing gradually. Technavio's analysts have predicted that the von Willebrand disease treatment market will register a CAGR of almost 7% by 2023.

Market Overview

Rising number of assistance programs for patients

The rising number of assistance programs for patients who need treatment of von Willebrand disease is pushing growth in the von Willebrand disease treatment market.

Cost intensive treatment

High cost of treatment is one of the major challenges for patients with VWD. As VWD is one of the very rare blood diseases, the patient pool available for carrying out clinical trials is negligible, which increases the research cost.

For the detailed list of factors that will drive and challenge the growth of the von Willebrand disease treatment market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated and with the presence of few companies including Baxter and CSL the competitive environment is quite intense. Factors such as the increasing awareness about VWD and the rising number of assistance programs for patients, will provide considerable growth opportunities to von Willebrand disease treatment manufactures. Baxter, CSL, Octapharma, Shire, and Grifols are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.'

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Desmopressin - Market size and forecast 2018-2023
  • Replacement therapy - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • Shire

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global rare disease drugs market
  • Exhibit 02: Segments of global rare disease drugs market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Inheritance of VWD
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Desmopressin - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Desmopressin - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Replacement therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Replacement therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by product
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Reimbursement programs in North America for hemophilia and its related diseases
  • Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Americas
  • Exhibit 34: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in EMEA
  • Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in APAC
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Patient assistance programs
  • Exhibit 43: Special drug designations
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Baxter - Vendor overview
  • Exhibit 51: Baxter - Business segments
  • Exhibit 52: Baxter - Organizational developments
  • Exhibit 53: Baxter - Geographic focus
  • Exhibit 54: Baxter - Segment focus
  • Exhibit 55: Baxter - Key offerings
  • Exhibit 56: Baxter - Key customers
  • Exhibit 57: CSL - Vendor overview
  • Exhibit 58: CSL - Business segments
  • Exhibit 59: CSL - Organizational developments
  • Exhibit 60: CSL - Geographic focus
  • Exhibit 61: CSL - Segment focus
  • Exhibit 62: CSL - Key offerings
  • Exhibit 63: CSL - Key customers
  • Exhibit 64: Grifols - Vendor overview
  • Exhibit 65: Grifols - Business segments
  • Exhibit 66: Grifols - Organizational developments
  • Exhibit 67: Grifols - Geographic focus
  • Exhibit 68: Grifols - Segment focus
  • Exhibit 69: Grifols - Key offerings
  • Exhibit 70: Grifols - Key customers
  • Exhibit 71: Octapharma - Vendor overview
  • Exhibit 72: Octapharma - Organizational developments
  • Exhibit 73: Octapharma - Key offerings
  • Exhibit 74: Octapharma - Key customers
  • Exhibit 75: Shire - Vendor overview
  • Exhibit 76: Shire - Business segments
  • Exhibit 77: Shire - Organizational developments
  • Exhibit 78: Shire - Geographic focus
  • Exhibit 79: Shire - Key offerings
  • Exhibit 80: Shire - Key customers